Elevance Health stock costs EUR 371.95 with P/ E 18.5
Published on 10/09/2026 at 20:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Elevance Health stock was at EUR 371.95 at Lang & Schwarz on October 9, 2026 at 8:04 p.m. CEST, up 2.79 percent versus EUR 361.85.
- The NYSE quote stood at USD 416.21 at 2:05 p.m. EDT, 4.59 percent below its USD 436.24 52-week high.
- Barclays raised its target from USD 457.00 to USD 469.00 on October 7, 2026, putting the target 12.69 percent above the NYSE quote.
- Third-quarter 2026 results are scheduled for October 21, 2026.
Elevance Health stock was at EUR 371.95 at Lang & Schwarz on October 9, 2026 at 8:04 p.m. CEST, plus 2.79 percent versus the prior close of EUR 361.85. The price comes with a P/E ratio of 18.5 and an NYSE quote of USD 416.21 at 2:05 p.m. EDT.
Price sits below yearly high
The NYSE price was 4.59 percent below the 52-week high of USD 436.24 and 51.43 percent above the low of USD 274.84 on October 9, 2026. Trading volume stood at 1,248,089 shares, versus an average volume of 1,185,975 shares, a 5.24 percent increase.
Valuation and targets
Market capitalization was USD 90.3 billion and the P/E ratio was 18.5 as of October 9, 2026. According to Markets Insider on October 7, 2026, Barclays raised its target from USD 457.00 to USD 469.00 and kept an Overweight rating. The target lies 12.69 percent above the NYSE price.
According to MarketBeat on October 6, 2026, 15 of 23 analysts recommended buying the stock and eight recommended holding it. The average 12-month target was USD 440.90.
Comparison with peers
Elevance Health: plus 2.79 percent, P/E 18.5, market capitalization USD 90.3 billion
UnitedHealth Group (NYSE, USD): plus 2.33 percent, P/E 24.4, market capitalization USD 344.7 billion
Humana (NYSE, USD): plus 12.15 percent, P/E 41.1, market capitalization USD 52.1 billion
Next results date
According to Elevance Health in its October 5, 2026 release, third-quarter 2026 financial results are scheduled for October 21, 2026, before the conference call at 8:30 a.m. EDT.
After-hours price
The Lang & Schwarz price was EUR 371.95 at 8:04 p.m. CEST on October 9, 2026, plus 2.79 percent versus the prior close of EUR 361.85 on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.
Elevance Health stock facts
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 9, 2026, 8:04 p.m. CEST): EUR 371.95
- Change versus prior close: plus 2.79 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 361.85
- Market capitalization: USD 90.3 billion (as of October 9, 2026)
- 52-week range: USD 274.84-436.24 (as of October 9, 2026)
- Index membership: S&P 500
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
